Introducing Sigyn Therapy™, a broad-spectrum blood purification technology created to address pathogen sources that precipitate the cytokine storm* underlying sepsis (# 1 cause of hospital deaths) and other life-threatening inflammatory disorders.
In the United States, the annual financial burden to treat sepsis alone is estimated to be $24 billion.*
Beyond sepsis, Sigyn Therapy is a candidate to address community-acquired pneumonia, emerging pandemic threats and inflammation & endotoxemia that commonly occurs in end-stage renal disease (ESRD) patients.
Prior to establishing Sigyn Therapeutics, our co-founders played instrumental roles in the development of three different technologies that the United States Food and Drug Administration (FDA) has permitted for use to treat COVID-19 infected individuals.
Stay informed and receive company updates straight to your inbox.
